Welcome to Sequence Card of Peptide


Details of CancerPDF entry with Sequence KVEQAVETEPEPEL
Primary information
sequence IDSeq_4450
Peptide sequenceKVEQAVETEPEPEL
CancerPDF_ID CancerPDF_ID315, CancerPDF_ID1707, CancerPDF_ID2964, CancerPDF_ID9581,
PMID19795908,21136997,21136997,21533267
Protein NameApolipoprotein E,Apolipoprotein E,Apolipoprotein E,Apolipoprotein E
UniprotKB Entry NameAPOE_HUMAN,APOE_HUMAN,APOE_HUMAN,APOE_HUMAN
FluidPlasma,Serum,Plasma,Serum
M/Z799.398,1596.78828,1596.7883,799.37
Charge2,1,1,2
Mass (in Da)NA,NA,NA,NA
fdrNA,NA,NA,NA
Profiling TechniqueLC-MS,LC-MS,LC-MS,LC-MS
Peptide Identification techniqueMALDI-TOF/TOF,LC-MS-MS/MS,LC-MS-MS/MS,LC/MS/MS
Quantification TechniqueLC-MRM (multiple reaction monitoring),LC-ESI-MS,LC-ESI-MS,Multiple Reaction Monitoring
Labelled/Label FreeLabelled,Label Free,Label Free,Label Free
FDRless than 7%,NA,NA,1.49
CancerPDF_ID CancerPDF_ID315, CancerPDF_ID1707, CancerPDF_ID2964, CancerPDF_ID9581,
p-ValueNA,NA,NA,NA
SoftwareFlexAnalysis 3.0 and Biotools 3.0 software,MASCOT(v. 2.2.01),MASCOT(v. 2.2.01),MASCOT
Length14,14,14,14
Cancer TypeDuctal adenocarcinoma of the pancreas (DAP),Colorectal cancer,Normal,Lung adenocarcinoma
DatabaseNCBI refseq Protein Database,SwissProt Database,SwissProt Database,Swissprot Database (57.4)
ModificationNA,NA,NA,NA
Number of Patients"41 normal, 28 patients",30 patients and 30 healthy controls,27 healthy individuals,62 lung adenocarcinoma and 30 healthy control
RegulationNA,NA,NA,"Differentially expressed between earlier-stage lung cancer group (stage-I, II, and IIIa) vs normal"
ValidationNA,Leave One out Cross validation,Leave One out Cross validation,MRM-based validation of 19 candidates
SensitivityNA,NA,NA,NA
SpecificityNA,NA,NA,NA
AccuracyNA,NA,NA,NA
Peptide AtlasPeptideAtlas
IEDB